

# 4D pharma PLC

20:43 21 Mar 2018

## 4D Pharma bullish on progress of microbiome-based cancer research

4D Pharma PLC (LON:DDDD) will present data today outlining how its microbiome-based cancer treatment might activate the body's response to the disease.

The company's lead oncology candidate is MRx0518, a strain of live bacteria extracted from human faecal samples that in pre-clinical models has shown it can stimulate the immune system.

Duncan Peyton, chief executive, will highlight aspects of the mode of action of MRx0518 at the Microbiome R&D and Business Collaboration Forum in Rotterdam.

### Specific component

4D has identified a specific component of the bacteria, flaA, that plays a key role in the activity of MRx0518 and the body's response to cancer.

Peyton said: "This is a key step in the development of a true microbiome-derived pharmaceutical product for the treatment of cancer.


"Understanding the mode of action of MRx0518, through the identification of a specific gene product and its interaction with a high profile human oncology target, gives greater insight into its potential applications and benefits to cancer patients."

Plans are at an advanced stage to open clinical studies for MRx0518 in the UK and the US in the near future.

**Price:** 93

**Market Cap:** £122.2 m

### 1 Year Share Price Graph



December 2019 June 2020 November 20

### Share Information

**Code:** DDDD

**Listing:** LSE

<b>52 week</b>	<b>High</b>	<b>Low</b>
	183	23.5

**Sector:** Pharma & Biotech

**Website:** [www.4dpharmapl.com](http://www.4dpharmapl.com)

### Company Synopsis:

*4D&nbsp;are pioneers in harnessing bacteria as a revolutionary new class of medicines - called live biotherapeutics.*

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).